PPARA and metabolic dysfunction-associated steatotic liver disease: Short and long-term DOX treatment can induce IR, hyperglycemia, and hyperlipidemia, increase hepatic FFAs contents, stimulate hepatic de novo lipogenesis, and promote NAFLD through several pathways, including stimulating adipose tissue lipolysis by activating PPARα [25].